Mimedx (MDXG) Total Current Liabilities (2010 - 2026)
Mimedx recorded quarterly Total Current Liabilities of $44.6 million in Q1 2026, down 30.68% quarter-over-quarter from $64.3 million in Q4 2025, and up 4.53% year-over-year from $42.6 million in Q1 2025.
Mimedx's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $44.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 4.53% year-over-year to $44.6 million; the TTM figure through Mar 2026 stood at $44.6 million (up 4.53% YoY), while the FY2025 annual figure was $64.3 million, up 40.95% from the prior year.
- Total Current Liabilities came in at $44.6 million for Q1 2026 at Mimedx, down from $64.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $64.3 million in Q4 2025 to a low of $36.6 million in Q1 2022.
- A 5-year average of $45.1 million and a median of $43.6 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities slumped 33.96% in 2022 and soared 40.95% in 2025, its largest moves.
- Mimedx's Total Current Liabilities stood at $43.6 million in 2022, then advanced by 5.63% to $46.0 million in 2023, then slipped by 0.9% to $45.6 million in 2024, then jumped by 40.95% to $64.3 million in 2025, then sank by 30.68% to $44.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $44.6 million, $64.3 million, and $57.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 44.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.55 Mn |
| Dec 31, 2025 | 64.27 Mn |
| Sep 30, 2025 | 57.68 Mn |
| Jun 30, 2025 | 50.29 Mn |
| Mar 31, 2025 | 42.62 Mn |
| Dec 31, 2024 | 45.60 Mn |
| Sep 30, 2024 | 41.94 Mn |
| Jun 30, 2024 | 40.01 Mn |
| Mar 31, 2024 | 42.22 Mn |
| Dec 31, 2023 | 46.01 Mn |
| Sep 30, 2023 | 43.63 Mn |
| Jun 30, 2023 | 44.46 Mn |
| Mar 31, 2023 | 40.87 Mn |
| Dec 31, 2022 | 43.56 Mn |
| Sep 30, 2022 | 45.86 Mn |
| Jun 30, 2022 | 37.14 Mn |
| Mar 31, 2022 | 36.59 Mn |
| Dec 31, 2021 | 42.36 Mn |
| Sep 30, 2021 | 41.75 Mn |
| Jun 30, 2021 | 50.57 Mn |
| Mar 31, 2021 | 55.41 Mn |
| Dec 31, 2020 | 59.16 Mn |
| Sep 30, 2020 | 57.30 Mn |
| Jun 30, 2020 | 63.66 Mn |
| Mar 31, 2020 | 63.70 Mn |
| Dec 31, 2019 | 67.32 Mn |
| Sep 30, 2019 | 73.40 Mn |
| Jun 30, 2019 | 78.10 Mn |
| Mar 31, 2019 | 64.30 Mn |
| Dec 31, 2018 | 71.55 Mn |
| Dec 31, 2017 | 45.81 Mn |
| Sep 30, 2017 | 35.16 Mn |
| Jun 30, 2017 | 51.51 Mn |
| Mar 31, 2017 | 49.60 Mn |
| Dec 31, 2016 | 60.79 Mn |
| Sep 30, 2016 | 41.58 Mn |
| Jun 30, 2016 | 38.54 Mn |
| Mar 31, 2016 | 28.84 Mn |
| Dec 31, 2015 | 26.78 Mn |
| Sep 30, 2015 | 24.35 Mn |
| Jun 30, 2015 | 19.46 Mn |
| Mar 31, 2015 | 18.46 Mn |
| Dec 31, 2014 | 18.40 Mn |
| Sep 30, 2014 | 14.45 Mn |
| Jun 30, 2014 | 9.91 Mn |
| Mar 31, 2014 | 9.59 Mn |
| Dec 31, 2013 | 9.61 Mn |
| Sep 30, 2013 | 8.33 Mn |
| Jun 30, 2013 | 6.14 Mn |
| Mar 31, 2013 | 5.97 Mn |
| Dec 31, 2012 | 5.02 Mn |
| Sep 30, 2012 | 10.55 Mn |
| Jun 30, 2012 | 8.24 Mn |
| Mar 31, 2012 | 6.80 Mn |
| Dec 31, 2011 | 4.73 Mn |
| Sep 30, 2011 | 6.83 Mn |
| Jun 30, 2011 | 5.56 Mn |
| Dec 31, 2010 | 1.25 Mn |